%0 Journal Article
%T Efficacy of pembrolizumab for patients with both high PD©\L1 expression and an MET exon 14 skipping mutation: A case report
%A Hiroaki Sakamoto
%A Hisashi Tanaka
%A Junichiro Tsuchiya
%A Kageaki Taima
%A Keisuke Baba
%A Masamichi Itoga
%A Sadatomo Tasaka
%A Toshihiro Shiratori
%A Yoshiko Ishioka
%J Archive of "Thoracic Cancer".
%D 2019
%R 10.1111/1759-7714.12939
%X Pembrolizumab has become the standard first©\line treatment for non©\small cell lung cancer (NSCLC) patients with high PD©\L1expression. MET exon 14 skipping is a rare mutation typically found in older, female, and non©\smoking patients with NSCLC. Herein, we report the case of a 71©\year©\old non©\smoking woman who was diagnosed with NSCLC in the left lung. EGFR mutation and ALK fusion were not detected. Because the biopsy specimen showed high PD©\L1 expression with a tumor proportion score of 95%, pembrolizumab was introduced as first©\line therapy, but resulted in no clinical benefit. The patient was subsequently administered chemotherapy with carboplatin and pemetrexed, leading to remarkable tumor shrinkage. A next©\generation sequencing panel analysis revealed a MET exon 14 skipping mutation. Thus, pembrolizumab might not be effective for NSCLC patients with MET exon 14 skipping mutations, even if PD©\L1 expression is high
%K MET exon 14 skipping mutation
%K non©\small cell lung cancer
%K pembrolizumab
%K pemetrexed
%K programmed death©\ligand 1
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360217/